Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Diseases 1Cytopenia 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 50fludarabine phosphate 47Busulfan 46Cyclosporine 36Antilymphocyte Serum 33Cytarabine 32Peripheral Blood Stem Cell Transplantation 30Radiotherapy 28Filgrastim 27Methotrexate 23Melphalan 23Mycophenolic Acid 21Cord Blood Stem Cell Transplantation 21Methylprednisolone 20Etoposide 17Whole-Body Irradiation 16Tacrolimus 15Daunorubicin 11Epoetin Alfa 10fludarabine 9Thiotepa 9Alemtuzumab 8Idarubicin 7Granulocyte Colony-Stimulating Factor 7sargramostim 6Topotecan 6Mitoxantrone 6Azacitidine 6Arsenic Trioxide 6Gemtuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × cedazuridine × Classical hematology × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡